(Q43703608)

English

Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

0 references

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

author name string

Rikje Ruiter

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Loes E Visser

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Myrthe P P van Herk-Sukel

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Petronella H Geelhoed-Duijvestijn

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sandra de Bie

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sabine M J M Straus

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Peter G M Mol

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Silvana A Romio

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Ron M C Herings

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Bruno H Ch Stricker

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

471-480

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1).

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Rosiglitazone: a European regulatory perspective.

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Changes in glitazone use among office-based physicians in the U.S., 2003-2009.

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis.

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006).

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Co-dispensing of contraindicated medications in patients using cisapride in Italy.

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.

1 reference

https://api.crossref.org/works/10.2165%2F11596950-000000000-00000

21 January 2018

[Diabetes mellitus in the Netherlands: estimate of the current disease burden and prognosis for 2025]

1 reference

https://pubmed.ncbi.nlm.nih.gov/22540371

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical consequences of disseminating the rosiglitazone FDA safety warning.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22540371

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert

1 reference

https://pubmed.ncbi.nlm.nih.gov/22540371

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events

1 reference

https://pubmed.ncbi.nlm.nih.gov/22540371

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11596950-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43703608&oldid=2206213346"